Welcome to Tenaci-T Therapeutics
Engineering T-Cell Receptors to Precisely Target Solid Tumors
Our T-cell receptors are carefully identified, selected, and validated to destroy tumor cells across lung cancer and other solid tumor types.
Core Technology
Transforming Immunotherapy Through Precision TCR Engineering
Tenaci-T Therapeutics was spun out of Dr. Alexandre Reuben's lab at MD Anderson Cancer Center. Over several years, Dr. Reuben's lab developed a TCR discovery pipeline which has enabled the validation of more than a dozen T cell receptors targeting some of the most prevalent antigens in lung cancer and other solid tumors. Tenaci-T Therapeutics aims to advance these receptors into the clinic.
Target
Discovery
TCR
Optimization
Experimental
Validation
Clinical
Translation
Tenaci-T Therapeutics
What Makes Us Different
Why Our T-Cell Receptor Platform Stands Apart
Target and HLA-degenerate TCRs with high tumor specificity to broaden the patient landscape.
High prevalence antigens/targets across solid tumors
Diverse HLA restrictions prevalent across patient populations in North America, Europe, and Asia
Different antigen classes including tumor-associated antigens, point mutations, indels, and duplications
Selected antigens are essential to the tumor phenotype, ensuring clonal expression and low intratumor heterogeneity
TCRs selected based on function rather than solely affinity
TCR-T exhibit ability to serially kill multiple targets
Extensive cross-reactivity and safety testing via X-scan and tissue/cell arrays
Antigens selected and TCR-T selected to overcome therapeutic resistance to standard of care
Who We Are
About Tenaci-T Therapeutics
Our mission is to provide potent and durable therapeutic options to patients with aggressive solid cancers.
We are committed to developing transformative T-cell receptor therapies that provide durable, targeted treatment options for patients with solid tumors.
Meet Our Team
Founder, Tenaci-T Therapeutics
Co-Founder, Tenaci-T Therapeutics
Consultant, Tenaci-T Therapeutics
Consultant, Tenaci-T Therapeutics
Consultant, Tenaci-T Therapeutics
Pipeline
TCR Pipeline
| Drug ID | Target | HLA | Indications |
|---|---|---|---|
| TTX-1 | TAA | HLA-A*02:01 | Lung Cancer, Glioblastoma, Pan-Cancer |
| TTX-2 | TAA | HLA-A*24:02 | Lung Cancer, Glioblastoma, Pan-Cancer |
| TTX-3 | EGFR | HLA-A*11:01 | Lung Cancer |
| TTX-4 | EGFR | HLA-A*03:01 | Lung Cancer |
| TTX-5 | KRAS | HLA-A*11:01 | Lung Cancer, Pancreatic Cancer, Colorectal Cancer |
| TTX-6 | KRAS | HLA-A*03:01 | Lung Cancer, Pancreatic Cancer, Colorectal Cancer |
| TTX-7 | HER2 | HLA-A*02:01 | Lung Cancer, Bladder Cancer, Breast Cancer |
| TTX-8 | HER2 | HLA-A*02:01 | Lung Cancer, Bladder Cancer, Breast Cancer |
Tenaci-T Therapeutics
News & Updates
Latest News
Study from MD Anderson highlights potential and impact of targeting FOXM1 transcription factor in lung cancer using TCR engineering.
-Tenaci-T Therapeutics hires Dr.
Jagannadha
Sastry, Ph.D., as Vice President,
Research
& Development
